Form 8-K NGM BIOPHARMACEUTICALS For: Feb 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral
February 27, 2024 8:47 AM ESTCiti analyst Samantha Semenkow downgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Buy to Neutral with a price target of $1.55 (from $6.00).
The analyst comments "NGM announced the company has entered into a merger agreement with affiliates of The Column Group (i.e., Atlas Neon... More
